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INTRODUCTION 
    Chronic Obstructive Airways Disease is acknowledged by the “WHO” as   the 
fourth   commonest cause of death worldwide. It is projected to be the third most 
common cause of death and fifth most common cause of chronic disability by the  
 year 2020. 
        Earlier in the 20th century TB was the major pulmonary disease in developing 
countries. Its place has been taken by two diseases in the later half of 20th century 
namely chronic obstructive airways disease and Carcinoma of lung. 
    Cigarette smoking is said to have been playing a major role in the etiology of  
Chronic Obstructive Airways Disease. Knowing the ill effects of smoking many  
governments including Indian Government have banned smoking in public places.         
This may in future lead to reduction in number of smokers and its ill effects thus  
 reducing the incidence of COAD in due course. 
        Chronic Obstructive Airways Disease is known to cause airflow 
limitations, impaired gas exchange and increased pulmonary artery pressure. 
According to literatures prevalence of pulmonary hypertension in chronic  
obstructive airways disease is 18%1. Elevated pulmonary artery pressure is a 
predictor of mortality in chronic obstructive airways disease.                 
“Weitzenblum” and coworkers2 showed a 72% 4 year survival in patients with 
normal pulmonary artery pressure compared with 49% survival in patients with  
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an elevated pulmonary artery pressure in Chronic Obstructive Airways 
Disease. 
           Both electrocardiography and echocardiography are very useful in the 
detection of elevated pulmonary artery pressure. Here an attempt has been 
made to correlate clinical features, pulmonary function tests,   
electrocardiography and echocardiography in case of Chronic Obstructive 
Airways Disease patients.   
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AIM OF THE STUDY 
 
          To analyze various cardiovascular manifestations of “Chronic 
Obstructive Airways Disease” with the help of Electrocardiography and 
Echocardiography. 
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REVIEW OF LITERATURE. 
          Chronic Obstructive Airways Disease. (COAD) 
          Chronic Obstructive Airways Disease is defined more clearly using the 
following,                                                                                                                                    
          British Thoracic Society3: 
          Chronic Obstructive Airways Disease is a condition that is characterized 
by airflow obstruction (FEV1 <80% predicted value & FEV1/FVC < 70%) 
which shows relentless progression & doesn’t change markedly either 
spontaneously or in response to treatment.                                                                            
          WHO/National heart lung & blood institute GOLD (Global     
initiative for   chronic Obstructive Lung Disease)4: 
          Chronic Obstructive Airways Disease is a disease state characterized by 
airflow limitation that is not fully reversible. The airflow limitation is usually 
both progressive & associated with an abnormal inflammatory response of the   
lungs to noxious particles and gases. 
          The American thoracic society: 
          The most recent definition, offered by the American Thoracic Society, 
defines chronic obstructive airways disease as a disease state characterized by 
the presence of air flow obstruction due to chronic bronchitis or emphysema;  
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the airflow obstruction is generally progressive, may be accompanied by 
airway hyperreactivity and may be partially reversible46.                                                               
           Other names of COAD 
                          -chronic obstructive pulmonary disease (COPD). 
                          -chronic obstructive lung disease (COLD). 
                          -chronic airflow limitation (CAL). 
          Chronic bronchitis and emphysema both constitute Chronic Obstructive 
Airways Disease.COAD is present only if chronic airflow obstruction occurs; 
Chronic bronchitis without chronic airflow obstruction is not included within 
COAD17. 
          Chronic bronchitis:                                                                                                        
          Chronic bronchitis is defined epidemiologically as a condition in which 
persistent cough with sputum production is present for at least 3 months for 2 
consecutive years5 . 
   Prognosis is linked to the presence of airflow obstruction and not  
sputum production.    
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          Emphysema:                                                                                                                    
          Emphysema is defined pathologically as an abnormal permanent 
dilatation of air spaces distal to the terminal bronchiole accompanied by 
destruction of the alveolar walls without obvious fibrosis6. 
 
 
 
Figure showing areas affected in emphysema. 
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          Etiology of Chronic Obstructive Airways Disease 
1) Tobacco use & cigarette smoking (active & passive) –major risk  
factors.15% of smokers develop COAD. 
2) Genetic: 
           Alpha 1 antitrypsin deficiency is associated with early onset progressive 
emphysema. This observation made by Laurel & Erickson11 led to the  
development of 1st plausible explanation for the pattern of lung destruction 
seen in Chronic Obstructive Airways Disease.             
          Alpha – 1- antitrypsin deficiency  
• Mutations involving alpha 1 antitrypsin gene. 
• Substitution of lysine for glutamic acid. 
• Polymerization of alpha 1 antitrypsin as a B-pleated sheet within  
hepatic mitochondria where it is synthesized. 
• No transportation into circulation. 
• Young patients affected. 
• Predominantly basal panacinar emphysema (smoking-  centriacinar  
emphysema more marked in upper lobes). 
• AR disorder 
3) Respiratory disease of prematurity, chronic untreated asthma,  
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childhood malnutrition, and low birth weight may play a role. Data reported by 
Barker & colleagues7 shows strong relationship between birth weight & lung 
function 5-6 decades later.                                                                                   
4) Occupational hazards such as toluene di-isocynate, coal dust (mine     
field workers) & redwood cedar. Occupational dusts appear to be most 
significant53, 54, and 55.          
          5)  Indoor pollution particularly cooking performed in poorly ventilated 
homes. 
          6) Bronchial hyper responsiveness-(Dutch hypothesis8)-Chronic          
Obstructive Airways Disease & Bronchial asthma form part of a spectrum of 
illness. The asthma in early life can progress to Chronic Obstructive Airways 
Disease later. The pathological data argues against this type of overlap which 
was determined by physiological testing. Long term studies, however, such as 
the Lung Health Study in USA has reported a high incidence of bronchial 
hyper reactivity to methacholine in smokers with mild Chronic Obstructive 
Airways Disease especially in women. Recent results from a large 25 year 
follow up study in the Netherlands indicate that increased airway 
hyperresponsiveness, defined by measured response to inhaled histamine, is an 
independent risk  factor for an accelerated decline in FEV156.                                         
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          7) Infections-(British hypothesis 9, 10)–recurrent infections with purulent  
sputum caused progressive Chronic Obstructive Airways Disease. This 
hypothesis was largely disproven by Fletcher & Peto.                               
          8) Low socieo economic status47. 
          Pathology: 
           - Persistent inflammation of airways as evidenced by elevated   
concentration of TNF alpha and IL 8 in induced sputum from patients with 
stable Chronic Obstructive Airways Disease & by increase in percentage of 
macrophages and neutrophils in broncho alveolar lavage specimens and 
induced sputum & by increased numbers of CD 45 lymphocytes with increased 
CD8 (T-suppressor) cells in endobronchial &peripheral lung biopsies12. The 
number of cells in airway wall is correlated with the FEV1. 
          - Oxidative stress13 caused by Reactive Oxygen Species (ROS) in the 
cigarette smoke. ROS are normally countered by both endogenous antioxidants 
(glutathione, uric acid, and bilirubin) & exogenous antioxidants (vit C & vit E 
in diet). Oxidative stress causes stiffening of neutrophil cell wall which reduces 
deformability & inhibits passage through pulmonary capillary bed. 
   - Mucus hyper secretion is caused by hypertrophied mucus glands. Loss 
of ciliated epithelia & short and thickened cilia cause impaired mucociliary  
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clearance and lead to accumulation of sputum. Increased number &size of 
goblet cells and degranulation changes that extend to peripheral airways 
contribute to peripheral airway plugging14                                     
          - Imbalance between proteinases like human neutrophil elastase & 
matrix - metallo protease and antiproteinases like alpha 1 AT causes 
destruction of lung tissue.  
           Careful quantitative studies suggest that there is diffuse loss of alveolar 
surface area proceeding in parallel with the more obvious macroscopic damage 
so that even normal lung adjacent to the damaged areas may not be free from 
diseases15. This helps to explain the relatively brief (i.e.12-24 months) benefits 
that follow lung volume reduction surgery where macroscopically damaged 
areas are removed. 
          Reid Index: 
          The ratio of the thickness of the submucosal glands to that of the 
bronchial wall is expressed as Ried index. 
           In normal individuals, it is 0.44 +0.09 
           In chronic bronchitis, it is    0.52+0.08 
           If the submucosal layer thickness is >50% of bronchial wall thickness it 
is highly suggestive of chronic bronchitis. 
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          High index is commonly associated with symptoms.  
           Pathophysiology: 
¾ Airflow limitations & increased airway resistance may be caused by  
loss of elastic recoil during passive exhalation due to emphysema, by increased 
collapsibility of small airways through loss of aerial traction of airways or to 
increased resistance due to intrinsic narrowing of small airways. As a direct 
consequence of altered pressure flow relationship, the work of breathing is 
increased in chronic bronchitis & emphysema.                                                                         
¾ Hyperinflation: 
           Dynamic hyper inflation contributes additionally to the discomfort 
associated with airflow obstruction by flattening the diaphragm & placing it at 
a mechanical disadvantage due to shortened diaphragmatic fiber length. 
¾ Inspired air exchange –small airway narrowing causes a decrease in  
ventilation of their distal alveolar acini when alveolar capillaries remain intact. 
This result in mismatching of ventilation & blood flow, decreased ventilation: 
perfusion ratio &mild to moderate hypoxemia.                     
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          Pulmonary vascular and cardiac changes:                                                                   
          There is inflammation in the pulmonary arteries even in early Chronic 
Obstructive Airways disease like that occurring in the adjacent airways. In 
severe cases thickening of arterial smooth muscle and reduplication of elastic  
lamina with extensive pulmonary arterial wall remodeling14, 15 are present. In 
patients with persistent day time arterial hypoxemia secondary to Chronic 
Obstructive Airways Disease right ventricular mass is increased. The extent of 
right ventricular hypertrophy is not however related to pulmonary arterial 
pressure measured in vivo rather it is correlated with the base line paO2 
experienced during the last year. There is hypertrophy of carotid bodies and 
increase in the size of glomerular tuft. 
          Clinical features. 
          Symptoms:             
• Cough with or without expectoration. 
• Breathlessness 
• Chest pain- may be related to intercostal muscle ischemia. 
• Rarely haemoptysis. 
• Weight loss in advanced disease. 
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          Signs: 
• Markers of smoking such as nicotine staining of fingers and teeth. 
• Non specific features of over inflation of the lungs with horizontal  
ribs, splaying of lower costal margin &widened xiphisternal angle. 
• Paradoxical inward movement of lower ribs (Hoover’s sign).       
• Cardiac dullness reduced. 
• Generalized reduction in the intensity of breath sounds –crude bed  
side indicator of reduced peak expiratory flow. 
• Occasional crepitations. 
• Expiratory wheezes. 
• Pursed lip breathing. 
• Elevated jugular venous pressure, pedal edema and tender  
hepatomegaly in case of right heart failure. 
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          Predominant Bronchitis versus Predominant Emphysema16 
No   Predominant Bronchitis Predominant  Emphysema 
1 General 
appearance 
Mesomorphic; 
Overweight; 
Dusky with suffused 
conjunctiva; Warm 
extremities. 
Often emaciated; Pursed lip 
breathing; Anxious; 
Prominent use of accessory 
muscles; Normal or cool 
extremities 
2 Age in years 40-50 50-75 
3 Onset of 
illness 
Cough Dyspnea 
4 Cyanosis Marked Slight to none 
5 Cough More evident than 
dyspnea. 
Less evident than dyspnea. 
6 Sputum Copious Scanty 
7 Upper RTIs Common Occasional 
8 Breath 
sounds 
Moderately diminished Markedly diminished 
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9 Cor 
pulmonale 
and  
Right heart 
failure 
Common Only during bout of RTI and 
also terminally. 
10 Radiography Normal diaphragmatic 
position; cardiomegaly; 
lungs normal or having 
increased bronchovascular 
markings.    
Small tubular heart; low flat 
diaphragm; Area of increased 
radiolucency 
11 Course of 
illness 
Ambulatory but constantly 
on verge of right heart 
failure and coma 
Incapacitating breathlessness 
punctuated by life 
threatening bouts of upper 
RTIs; Prolonged course 
culminating in right heart 
failure and coma. 
 
          Complications of COAD. 
¾ Secondary polycythemia 
¾ Right heart failure 
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¾ Pneumothorax 
¾ Respiratory failure. 
           Prognosis and predictors of survival. 
          Chronic Obstructive Airways Disease is a progressive disease and a 
patient’s lung function can be expected to deteriorate over time even with best 
available care. Although pulmonary hypertension progresses slowly in patients 
with Chronic Obstructive Airways Disease its presence confers a poor 
prognosis. 
¾ “Weitzenblum and coworkers”: 
           72% 4 years survival rate in patients with normal pulmonary artery 
pressure compared with a 49% survival rate in those with an elevated 
pulmonary artery pressure(mean  >20mmHg).  
¾ “Professor Richard Doll & colleagues”9,18. 
          Mortality from Chronic Obstructive Airways Disease was 17 times 
greater in smokers compared with non smokers. 
¾ “Fletcher & Peto Classic study of U.K. postal workers”                                             
          Rate of decline of lung function (FEV1) was greater in smokers. Normal 
loss of FEV1 of 15-30ml/year increases to >60ml/year in current smokers and 
>40ml/year in ex. Smokers. Not all smokers develop this accelerated loss of  
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lung function & conventional wisdom  holds that only 15-20% of smokers are 
affected. 
¾ Onset of hypercapnia is often first noted during an exacerbation but  
when present persistently it carries poor prognosis19. 
¾ Low body mass index (<19) is an independent risk for premature  
death20. 
¾ By the time patients are hospitalized with an exacerbation of COPD,  
they have a poor prognosis especially if they have developed respiratory 
failure. In one unselected North American series of patients who were followed 
post discharge from ICU, one third of patients had died within 12 months21. 
¾ A study with a 10 year follow up  conducted on a cohort of 870  
patients with severe Chronic Obstructive Airways Disease22 concluded that 
patients with Chronic Obstructive Airways Disease have a high mortality rate 
from acute respiratory failure, cor pulmonale and lung cancer. Patient’s age at 
the time of diagnosis influences death risk. Patients who need long term 
oxygen treatment have a higher death risk than those who do not need. The 
higher the FEV1 or paO2 at the time of diagnosis, the lower the death 
risk.Patients who need and use long term oxygen treatments have a lower death 
risk  than those who need it but do not use it properly. Patients with a partial  
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reversible airway obstruction who regularly attend the clinic for planned check 
ups have a lower death risk than those who have the same characteristics but do 
not show adherence to the care program. 
¾ In another study of 166 patients treated with long term oxygen  
therapy, the overall survival rates were 78.3 and 67.1 percent at 2 and 3 years, 
respectively23. 
¾ A multi variate analysis showed an independent predictive value for  
right ventricular systolic pressure, age and FEV124. 
¾   Once endotracheal intubation is necessary, the prognosis is usually     
poor and the survival after 1 year is usually lower than 40%25. 
¾ Pulmonary embolism is a common cause of death with the frequency  
estimated to be approximately 11 % among patients with Chronic Obstructive 
Airways Disease in the intensive care unit. Pulmonary embolism was the 
most frequent cause of death, at 40.6%26 
          Investigations:                                                                                     
          Respiratory function tests: 
          These measure the degree of airflow obstruction during forced expiration  
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          Spirometry:  
• Robust standard is dry bellows Spirometry such as vitallograph. 
• Cheaper alternative - Turbine wane & pneumotachograph – both  
measure flow and convert it into volume. 
• Normal curve has a brisk flow near total lung capacity, then a steady  
decline down to residual volume. Inspiratory limb is a smooth semicircle. 
• With the development of disease in small airways the expiratory limb  
begins to dip at lower volumes. 
• When a large degree of emphysema is present there is a characteristic  
flow volume loop with a sharp drop in flow after the initial peak as the pressure 
in the thorax collapses the airway. 
• In normal subjects there is little or no difference between the relaxed  
&forced vital capacity. 
• In emphysema forced vital capacity is less than relaxed vital capacity. 
• During measurement of FVC the procedure must continue until all  
possible volume is added.                                         
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          Staging of severity of COAD 
%Predicted FEV1 Staging 
British 
thoracic 
society 
European 
respiratory 
society 
American 
thoracic 
society  
Mild 60-79% > 70% >50% 
Moderate  40-59% 50-69% 35-49% 
Severe  <40% <50% <35% 
                                           A ratio of FEV1/ FVC is termed forced expiratory 
ratio.FEV1 <80% and FER <70% indicates COAD. 
          Transfer factor: 
          The transfer factor test for carbon monoxide measures the ability to 
move carbon monoxide from inhaled gas to hemoglobin in the alveolar 
capillaries. Carbon monoxide is used as a surrogate for oxygen.  
          The gas mixture inhaled contains a small amount of the inert gas helium. 
The helium concentration in the expired gas is lower than in inspired gas 
because of dilution with the residual gas in the lungs.                                                          
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          Carbon monoxide is reduced because of this dilution &transfer across the 
alveolar capillary membrane into the blood. The combination of the two allows 
an estimate of the amount of gas transfer into blood.                                            
          The result is expressed either as carbon monoxide transfer factor (TLCO) 
for the lungs or as transfer factor per unit volume accessed (diffusion 
coefficient or kCO). The kCO adjusts for the size of the lung accessed by the 
inspired gas, for example a large pleural effusion will reduce lung volume & 
TLCO but not the kCO since gas transfer is normal within the lung accessed by 
the inspired gas. 
          Asthma may reduce TLCO when severe but kCO tends to be high in 
asthma. Emphysema with its destruction of alveolar capillary membrane results 
in large air space, decreased area for gas transfer & reduction of TLCO & kCO. 
          In Chronic Obstructive Airways Disease, the reduction in kCO is a guide 
to the extent of emphysema. Other restrictive conditions such as fibrosing 
alveolitis reduce kCO but within the obstructive lung conditions, reduced kCO 
is a marker for emphysema. There is good direct & indirect evidence that the 
severity of emphysema is well related to the reduction in TLCO although this 
relationship is lost when their FEV1 falls below 1 & TLCO becomes more  
difficult to measure.                                                                                         
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          Body Plethysmography: 
          The helium dilution method & the body plethysmograph method can 
produce different values for lung volumes since the body plethysmograph 
measures all the gas within the thorax that is subject to the pleural pressure 
changes. 
          The helium dilution only measures the volume accessible to inspired air. 
Poorly ventilated areas such as emphysematous bullae will be included in the 
plethysmograph volume but may not show on the helium dilution.  
          This difference, the trapped gas has been used as an estimate of extent of 
lung damage in Chronic Obstructive Airways Disease. After administration of 
bronchodilators the over inflation in Chronic Obstructive Airways Disease may 
be reduced. 
          This can occur in the absence of significant change in spirometry. Such 
deflation can reduce symptoms of breathlessness or increase exercise tolerance 
& can explain subjective benefits found in the absence of any change in 
spirometry 
          Blood Gases& Oximetry: 
          In the chronic stable situation blood gas examination is necessary to 
guide the provision of long term oxygen treatment. In acute exacerbations,  
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blood gas analysis helps to evaluate severity, prognosis & the need for oxygen 
treatment or respiratory support by invasive or non invasive means. 
          Blood gas analysis is still the only convenient way of assessing paCO2 
& should be considered in any patients with an FEV1 below 1.21 or 40% of the 
predicted value or whose oxygen saturation is less than 92%.  
          Oximetry provides a measure of oxygen saturation & a portable pulse 
oximeter is a very useful tool. The relationship between saturation & paO2 is 
given by the oxygen saturation curve. Oximeter transmits light as set 
wavelengths through tissue in the finger or ear lobe. Saturated & desaturated 
hemoglobin absorbs the wave lengths differently & allow a calculation of the 
percentage of hemoglobin that is saturated. It is accurate in most routine 
clinical situations although less reliable at saturation below 75% .When there is 
poor peripheral perfusion the signal may be inadequate or the reading 
inaccurate. In some circumstances, other pigments such as nail varnish or 
carboxyhemoglobin produce inaccurate results.                                                                         
          Pulse oximetry provides a very special useful measurement. It is 
important to remember however that it measures only the oxygen level & 
doesn’t provide a measurement of the level of carbon dioxide. In acute  
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exacerbations, patients receiving supplemental oxygen may have marked 
carbon dioxide retention with inappropriately reassuring oxygen saturation. 
          In acute exacerbations requiring admission to hospital, baseline arterial 
blood gas analysis is usually necessary. 
          Assessment of blood gas is an essential part of the criteria for provision 
of long term home oxygen. If the baseline oxygen saturation of breathing air is 
above 92% then arterial pO2 is not likely to meet the criteria for long term 
home oxygen. Oximetery therefore provides a useful screening test to see 
whether it is appropriate to go on to measure arterial blood gas.   
          X-Ray Chest: 
¾ Emphysematous changes  
¾ Increased pulmonary vascular markings 
¾ Pulmonary artery dilatation 
¾ Cardiomegaly   
          Detection of pulmonary hypertension in COAD. 
          X-Ray Chest 
          Chest radiography is poorly sensitive in the diagnosis of pulmonary 
hypertension. 
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          Electrocardiographic findings in Chronic Obstructive Airways 
Disease27. 
¾ P pulmonale- P wave amplitude > 2.5 mm in standard leads together  
with right p wave axis. 
¾ Right QRS axis deviation directed to the region of +90 degrees  
clockwise to +150 degrees.                                                
¾ Left QRS axis deviation in 10% of cases. 
¾ SІ, SП, SШ syndrome – prominent S waves in standard leads І, П,  
and Ш.This indirectly reflects posterior displacement of the apex. Rather wide 
and slurred S wave may appear in all three standard leads & leads V4 to V6. 
¾ Complete/ incomplete right bundle branch block. 
¾ R/s >1 in V1 or R wave amplitude in V1 >5 mm. 
¾ r/S < 1 in v6 or r wave in V6 < 5mm,trasition zone is frequently  
displaced to lead V6 or even further to left.  
¾ Small QS or w shaped complexes in right precardial leads. 
¾ Diminution of QRS magnitude in all the precardial leads. Small r  
waves may completely disappear in right precardial leads. 
¾ T wave - decrease in amplitude in all leads, may be inverted in  right  
precardial leads. 
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 These abnormalities are usually less pronounced in patients with Chronic  
Obstructive Airways Disease than in patients with other forms of pulmonary 
hypertension because of modest degrees of pulmonary hypertension that occurs 
and because of effects of hyperinflation. ECG changes have a good specificity 
(85%) but their sensitivity is poor (40%), particularly in patients with mild 
pulmonary hypertension65.  
          Echocardiographic findings of pulmonary hypertension in Chronic 
Obstructive Airways Disease23, 31.                                                                                           
          Poor window due to over inflation and sub optimal images due to 
marked respiratory variation in intra thoracic pressure make the performance of 
ECHO in Chronic Obstructive Airways Disease patients a difficult job. 
Although the correlation between systolic pulmonary artery pressure measured 
by echocardiography and that measured at the time of cardiac catheterization 
was good 52% of pressure measurements were found to be inaccurate. There 
was more than 10mm Hg difference between the two. Further > 48% of 
patients were misclassified as having pulmonary hypertension by 
echocardiography  
¾ Increased pulmonary artery pressure.  
¾ Tricuspid regurgitation. 
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¾ Right ventricular wall thickening. 
¾ Increased right ventricular volume. 
¾ Reversed movement of the interventricular septum. 
¾ Enlargement of right atrium and ventricle. 
¾ Normal or small left ventricular dimensions. 
          Echocardiographic findings that portend a poor prognosis include 
pericardial effusion, right atrial enlargement and septal displacement. 
          Measurement of pulmonary artery pressure by echocardiography. 
          None of the echocardiographic techniques measure the intravascular 
pressure directly. The use of Doppler echocardiography for determining a 
pressure involves the use of tricuspid regurgitant jet and the Bernoulli equation. 
By determining the right ventricular outflow tract one can determine the 
pulmonary artery systolic pressure. This technique is probably the most 
accurate for quantification of pulmonary artery pressure. 
          Doppler recordings of the pulmonary artery velocity can also provide an 
assessment of pulmonary artery pressure and pulmonary vascular resistance. 
The measurements that have been used include the pre ejection period which is 
the time interval from the onset of electrocardiographic QRS to the onset of 
pulmonary artery systolic flow, the acceleration time which is the time between  
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the onset of flow to the peak systolic flow and the ejection time which is the 
interval from the onset to the cessation of flow.                              
          Echo Doppler techniques have become the non invasive standard to 
detect pulmonary hypertension68, 70. These techniques are relatively accurate 
when pulmonary artery pressure ( PAP) is above 30mmHg, but they do not 
detect milder pathologic pulmonary hypertension. Echo Doppler is useful for 
longitudinal follow up of pharmacologic treatment of pulmonary hypertension 
& cor pulmonale. In a recent study the bias of Doppler ECHO in the 
measurement of systolic PAP compared with right heart catheterization(RHC) 
was 2.8 mm Hg which is high when one takes into account the modest level of 
PHT in most COAD patients71. 
          B-Type natriuretic peptide (BNP): 
          B- Type natriuretic peptide (BNP) release is due to increased wall stretch 
of atria and may have a relatively good sensitivity and specificity for the 
identification of pulmonary hypertension in COAD patients66, 67. However 
larger studies are needed to determine the benefit of BNP plasma level in the 
diagnosis of pulmonary hypertension in COAD. 
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          Right heart catheterization.                       
          Right heart catheterization is the gold standard for diagnosis of 
pulmonary hypertension68, 69. It allows the direct measurement of pressure in 
the right atrium, the right ventricle, the pulmonary artery and in the wedge 
position to estimate left heart filling pressures. RHC is generally carried out  
using a Swan- Ganz catheter type. RHC has two drawbacks: First it is an 
invasive procedure having some risk.  Next it needs hospitalization which may 
be inconvenient for patients. 
            
          Predominant Bronchitis versus Predominant Emphysema72. 
SI 
NO 
 Predominant 
bronchitis 
Predominant emphysema 
1 FEV1/FVC Reduced Reduced 
2 FRC Mildly increased Markedly increased 
3 TLC Normal or slightly 
increased 
Considerably increased 
4 RV Moderately increased Markedly increased 
5 Lung compliance Normal or low Normal or low 
6 Recoil pressure Normal or high Low 
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7 MVV Moderately decreased Markedly decreased 
8 Airway resistance Increased Normal or slightly 
increased  
9 DLCO Normal or low Low 
10 Arterial Po2 Moderately to 
severely reduced 
Slightly to moderately 
reduced 
11 Arterial 
hypercapnea 
Chronic Only during acute 
respiratory infection 
12 Hematocrit Generally high, may 
reach 70% 
Normal or slightly high, 
rarely above 55% 
13 Pulmonary artery 
pressure 
Generally increased Normal or slightly 
increased 
                          
          Management:                                                                                                                   
          The overall approach to the management of stable Chronic Obstructive 
Airways Disease should revolve around a stepwise increase in treatment, 
depending on the severity of the disease. Disease severity is determined by the 
severity of symptoms and air flow limitation as well as other factors, including 
the frequency and severity of exacerbations, complications, respiratory failure, 
and comorbid factors, including cardiovascular disease and sleep –related  
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disorders, in addition to the general health status of the patients. Patient’s 
education is paramount to effective treatment of COAD. 
          Smoking cessation:  
          The Lung health study reported that patients who stopped smoking had a 
small improvement in FEV1 (57ml) after 1 year. Thereafter the rate of decline 
in lung function is similar to that of age matched non smokers28. 
           Numerous studies indicate that nicotine replacement therapy in any form 
(gum, inhaler, nasal spray, transdermal patch, sublingual tablets, or lozenges)  
reliably increases long term smoking abstinence rates29. The anti depressants 
bupropion or nortriptyline have also been shown to increase long term smoking 
cessation rates, although fewer data are available30. 
          Pulmonary rehabilitation: 
          The goals of pulmonary rehabilitation in COAD patients are to reduce 
symptoms, improve quality of life, and increase physical and emotional 
participants in everyday activities. Although a large study of 200 patients with 
disabling Chronic obstructive airways disease demonstrated no difference in 
hospital admission among the patients randomized to receive rehabilitation 
versus the control patients, the rehabilitation group showed greater  
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improvement in walking ability and general and disease –specific health 
status32. 
          Pharmacological treatment: 
          Bronchodilators and corticosteroids: 
          Bronchodilators are used as either during exacerbations of COAD or on 
a regular basis to prevent or reduce symptoms. A combination of short acting 
beta 2 agonist and an anti cholinergic agent in stable chronic obstructive 
airways disease patients produces greater sustained improvements in FEV1 
than either agent alone and does not produce evidence of tachyphylaxsis over 
90 days of treatment. 
          Prolonged treatment with corticosteroids does not modify the long term 
decline in lung function in patients with Chronic obstructive airways disease 
and primarily be used in those who have a documented spirometric response to 
inhaled corticosteroids33. 
          Antibiotics: 
          Antibiotics are very useful during exacerbations of chronic obstructive 
airways disease.  
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          Vasodilators:  
          The use of vasodilators has been disappointing in the treatment of 
chronic obstructive airways disease patients even those with pulmonary 
hypertension. Because of potential for worsening ventilation-perfusion 
mismatch vasodilators may even worsen hypoxemia. 
           Digoxin: 
           Data recording the use of digoxin in chronic obstructive airways disease 
patients is insufficient to make recommendations although short term 
intravenous digoxin improved cardiac output and reduced circulating nor 
epinephrine levels in patients with right ventricular dysfunction34.           
          Vaccination: 
          Influenza and pnuemococcal vaccines are recommended. 
          Alpha 1 anti trypsin deficiency:  
          Weakly or monthly injections of alpha 1 anti trypsin.  
          Long term home oxygen 
           In key clinical trials long term oxygen therapy clearly improved the 
survival of hypoxemic patients with chronic obstructive airways disease35, 36. 
The British study37 compared the effect of treatment with oxygen 
approximately for 15 hours per day with the effects of no oxygen therapy. The  
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NIH study35 compared nocturnal oxygen therapy (about 12 hours per day) to 
continuous oxygen therapy atleast 19 hours per day .Oxygen therapy was 
beneficial in both studies. Continuous therapy is more effective than nocturnal 
therapy alone. 
          Haemodynamic effects of oxygen: 
          1) Oxygen relieves pulmonary vasoconstriction, decreasing pulmonary 
vascular resistance and thus enabling the right ventricle to increase the stroke 
volume. 
           2) Oxygen therapy improves arterial oxygen content, providing 
enhanced oxygen delivery to the heart, brain and other vital organs. These two 
hypotheses are not mutually exclusive, and each one has supporting evidence. 
I 
          Indications for Home Oxygen38: 
Absolute 
PaO2 < 55mm Hg or SaO2 <88% 
PaO2 55-59 mmHg or SaO2 = 89% in the presence of dependent 
edema, P pulmonale on the ECG, erythrocytosis (hematocrit >56%) 
Specific situations  
During exercisePaO2 < 55mmHg or SaO2 <88% with minimal exertion
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During sleep PaO2 <55mmHg or SaO2 <88 % with associated 
complications like PHT, excessive day time sleepiness and cardiac 
arrthymias. 
 
          Noninvasive ventilation: 
          Noninvasive positive pressure ventilation has been reported to improve 
gas exchange, sleep efficiency, quality of life and functional status in patients 
with restrictive lung disease and chronic respiratory failure; however its  
usefulness in patients with chronic obstructive airways disease is not as well 
established. Uncontrolled studies have demonstrated that non invasive positive 
pressure ventilation used at home may improve oxygenation and reduce 
hospital admissions in patients with severe chronic obstructive airways disease 
and hypercapnea and improve long term survival, although large controlled 
clinical trails are now needed39. The combination of noninvasive positive 
pressure ventilation and long –term O2 therapy may be more effective40, but 
again large trails are needed before this approach can be recommended. 
          Lung volume reduction surgery:  
          Volume reduction surgery, which was originally described by Brantigan, 
has been advocated in selected patients with advanced emphysema. The 
surgical technique involves removing 20-30 % of the volume of each lung by  
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means of sternotomy, sequential thoracotomy, or thoracoscopy to reduce the 
severe hyperinflation commonly seen in patients with severe chronic 
obstructive airways disease. 
          A randomized trail comparing the results of lung volume reduction with 
medical therapy for severe emphysema has been completed41. A total of 1218 
patients with severe emphysema who underwent pulmonary rehabilitation were 
randomly assigned to undergo lung volume reduction surgery or to receive  
continued medical therapy. An interim analysis determined that patients with a 
FEV1 of less than 20 % of predicted and either homogenous distribution of 
emphysema on CT scan or carbon monoxide diffusing capacity that was 20% 
or less of the predicted value were at high risk for death after lung volume 
reduction surgery with a low probability of functional benefit42. Among 
patients with predominantly upper lobe emphysema and low exercise capacity, 
the mortality rate was lower in the surgery group than in the medical therapy 
group. Among patients with non –upper lobe emphysema and high exercise 
capacity, the mortality rate was higher in the surgery group than in the medical 
therapy group. Lung volume reduction is a palliative procedure that does not 
halt, but only slows, the rate of functional decline for COAD.The disease will 
still progress, and symptoms may get worsened. 
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          Lung Transplantation: 
          Chronic obstructive airways disease is the most common indication for 
lung transplantation world wide. In 1995, approximately 60% of single lung 
and 30 % of bilateral lung transplantations were performed on patients with 
chronic obstructive airways disease43. Lung transplantation is a viable 
treatment option in patients with advanced pulmonary parenchymal or 
pulmonary vascular disease who have exhausted medical management.      
           Both single lung transplantation and bilateral lung transplantation result 
in significant improvement in post operative lung function, exercise capacity, 
and quality of life44. The choice of the procedure needs to be individualized. In 
general, single-lung transplantation is used for emphysema because of the 
scarcity of organ donars, lower perioperative morbidity and mortality rates, and 
comparable improvement in exercise capacity compared with bilateral lung 
transplantation45. However postoperative spirometry, single breath diffusing 
capacity, and arterial oxygen tension are all significantly higher in bilateral 
lung transplantation compared with single lung transplantation, which may 
benefit young patients with emphysema. 
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STUDY DESIGN 
          Aim: 
          To study Electrocardiographic and Echocardiographic changes in 
patients with “Chronic Obstructive Airways Disease”.                                                              
          Materials and Methodology: 
          Population:                                                                                                                       
          Patients attending the out patient clinic &who were admitted in 
“Government Royapettah Hospital, Chennai” with  complaints of  persistent 
cough with expectoration for 3 months in  two consecutive years or who have 
cough, breathlessness with clinical or x-ray evidence of hyper inflation  were 
selected for the study (50 patients). 
          Period of the study: 
           January 2008 –July 2008. 
          Inclusion criteria:                                                                                                            
          Patients with spirometric evidence of chronic obstructive airways 
disease. 
          Criteria for diagnosis of chronic obstructive airways disease - 
FEV1<80% predicted value & FEV1/FVC < 70%. 
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          Exclusion criteria: 
          Patients with TB, bronchial asthma, bronchiectasis, bronchogenic 
carcinoma, interstitial lung disease, coronary artery heart disease, systemic 
hypertension, aortic & mitral valve disease, right heart failure& patients 
residing at high altitude were excluded from the study by doing x-ray chest, 
Mantoux test, sputum for acid fast bacilli & blood pressure measurement. 
          Performance of spirometry: 
          Spirometry was done according to the guidelines published by both the 
British Thoracic Society (BTS) with the Association of Respiratory 
Technicians & Physiologists (ARTP) & the American Thoracic Society. 
According to these guidelines production of reliable results of spirometry is 
very dependent on the person performing the test. They must have the ability to 
encourage the patients to perform a maximal forced exhalation. 
          The patients were demonstrated the maneuver first. They were seated in 
a comfortable stool. They were asked to take deep full inspiration. Good seal 
was maintained with the mouth piece of spirometry.With maximum effort 
exhalation was continued for atleast 6 seconds and to a maximum of 15 
seconds.  The results of the measurement were accepted only if the trace is 
smooth & cough free. The maneuvers were  
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done thrice for each patients & the best FEV1 & the best FVC were recorded. 
Reversibility test with inhaled salbutomal was done to rule out bronchial 
asthma (reversibility more than 15%).       
           ECGs were taken and coronary artery heart disease was ruled out.                
           ECG evidence of pulmonary hypertension in chronic obstructive 
airways disease. 
¾ P pulmonale  
¾ Right QRS axis deviation  
¾ SІ, SП, SШ syndrome  
¾ Diminution of QRS magnitude in all the precardial leads.  
¾ R/s >1 in V1 or R wave amplitude in V1 >5mm. 
¾ r/S <1 in V5 or V6 or r wave in V6 <5mm. 
¾ Complete/incomplete right bundle branch block.  
          Echocardiographic evidence of pulmonary hypertension in COAD  
¾ Enlargement of right atrium and ventricle. 
¾ Normal or small left ventricular dimensions. 
¾ Thickened interventricular septum. 
¾ Reversed septal motion. 
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¾ Tricuspid regurgitant velocities –contrast enhancement with saline 
improves accuracy. 
¾ Doppler Echocardiographic quantification of right ventricular systolic 
hypertension can be obtained by measuring the velocity of the 
tricuspid regurgitant jet and using the Bernoulli formula.   
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OBSERVATIONS 
          Age distribution: 
                   
One-Sample Statistics
50 50.7000 8.14724 1.15219AGE
N Mean Std. Deviation
Std. Error
Mean
 
                 
Age group Frequency Percentage 
< 50 years 
51 -60 years 
 >61 years  
30 
16 
4 
60  
32 
8 
 
          Chronic obstructive airway disease is most prevalent in persons aged 
<50 years i.e., 60 % of patients are <50 years of age.                             
          Sex distribution:                    
Sex group Frequency Percentage 
Males 
Females 
49 
1 
98 
2 
 
          Chronic obstructive airways disease is most prevalent in males. 
           
 
      
 43
     Occupation details:                      
occupation Frequency Percentage 
Manual laborers 
Factory workers 
 
Shop owners 
Office staffs 
Home makers 
34 
1(cement factory 
worker) 
4 
10 
1 
68 
2 
 
8 
20 
2 
          Chronic obstructive airways disease is most prevalent in manual 
laborers i.e. 2/3 rd of patients are manual laborers. 
          Socio economic status:                   
Income group Frequency Percentage 
Low socio economic 
group 
Middle class people 
 
36 
 
14 
72 
 
28 
 
          Nearly 3/4th of chronic obstructive airways disease patients are from 
lower socio economic group. 
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     Smoking pattern:                          
Smoking pattern Frequency Percentage 
Smokers 
Non smokers 
36 
14 
72 
28 
          72% of chronic obstructive airways disease patients are smokers.83% 
of smokers (30 persons) still continue to smoke.                      
          Smoking intensity: 
Smoking intensity 
(No of cigarettes / day) 
Frequency Percentage 
Non regular smokers 
<5  
6-10 
11-20 
> 20 
3 
10 
10 
6 
7 
8 
28  
28 
17 
19 
 
          64% of smokers smoke <10 cigarettes per day.19% of smokers smoke 
more than 20 cigarettes per day. 
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          Age at which started smoking: 
Age at which started 
smoking 
Frequency Percentage 
< 20 years 
21-30 years 
>31 years 
18 
15 
3 
50 
42 
8 
          Most of the patients started smoking at earlier ages that is before 20 
years of age. 
          Air pollution                                                                                                                
          82% (41 persons) of chronic obstructive airways patients give H/O 
living in damp housing as well as exposed to passive smoking. One person 
works in cement factory.  
          Analysis of etiological factors 
Etiology  Frequency Percentage 
Smoking only  
Air pollution only 
Smoking +air pollution 
No aetiology given 
5 
11 
31 
3 
 
10  
22 
62 
6 
          62% of patients give history of exposure to both smoking and air 
pollution.6% of patients give history of no exposure to risk factors. 
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      X-ray chest findings: 
x-ray chest findings Frequency Percentage 
Emphysematous 
changes 
Increased pulmonary 
vascular markings. 
Pulmonary artery 
dilatation 
cardiomegaly 
22 
34 
 
6 
 
3 
44 
68 
 
12 
 
6 
 
          Pulse oximetry: 
SpO2 Frequency Percentage 
More than 88% 
<87% 
42 
8 
84 
16 
 
          84% of patients showed no evidence of hypoxemia.16% of patients 
had pulse oximetry evidence of hypoxemia. 
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          Interpretation of pulmonary function test: 
FEV1/FVC Frequency percentage 
70-61 
60-51 
<50 
31 
12 
7 
62 
24 
14 
         
One-Sample Statistics
50 1.2040 .17723 .02506
50 2.0280 .16418 .02322
50 59.0400 5.17829 .73232
PFT FEVI
PFT  FVC
FEV1/FVC
N Mean Std. Deviation
Std. Error
Mean
                  
 
         Interpretation of ECG: 
ECG findings Frequency Percentage 
 P pulmonale 
 QRS right axis     
deviation 
Right bundle branch 
block 
R/s > 1 in V1 
r/s <1 in V6 
Poor progression of R 
wave in right precordial 
leads. 
↓ Twave amplitude in 
right precordial leads. 
17 
14 
 
6 
 
4 
3 
5 
 
 
2 
34 
28 
 
12 
 
8 
6 
10 
 
 
4 
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          ECG evidence of pulmonary hypertension: 
ECG evidence of 
pulmonary hypertension 
Frequency Percentage 
Present 
absent 
23 
27 
46 
54 
 
          ECHO evidence of pulmonary hypertension: 
ECHO evidence of 
pulmonary hypertension 
Frequency Percentage 
Present 
Absent  
22 
28 
44 
56 
 
 
 
          ECHO findings in PHT 
ECHO findings Frequency Percentage 
Elevated PAP 
Tricuspid regurgitation 
Right atrial dilatation 
Pericardial effusion 
22 
6 
4 
1 
44 
12 
8 
2 
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          Severity of pulmonary hypertension: 
Pulmonary hypertension Frequency Percentage 
Severe(>50mm Hg) 
Moderate(31-50mmHg) 
Mild(<30mmHg) 
1 
7 
14 
2 
14 
28 
 
          Age group * ECHO evidence pulmonary hypertension: 
Age group No Echo 
E/O PHT 
Echo E/O 
PHT 
Total  
<50 years 19 11 30 
50-60 
years  
6 10 16 
>60 years 3 1 4 
Total 28 22 50 
p =o.177 not significant 
                                                                                                                                     
          Smoking * ECHO evidence:  
ECHO evidence of PHT           Smoking 
Absent  Present 
     Total  
Absent  
Present 
13 
15 
1 
21 
14 
36 
total  28 22 50 
 
p= 0.001 significant 
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          Air pollution *Echo evidence of PHT: 
Echo evidence of PHT Air pollution 
Absent  present 
Total  
Absent  
Present 
4 
24 
4 
18 
8 
42 
total 28 22 50 
p=0.709 not significant 
 
          Smoking intensity *Echo evidence of PHT 
Echo evidence of PHT Smoking 
intensity(cigarettes 
/day) 
Absent  Present 
Total 
No smoking 13 1 14 
<5 7 6 13 
6-10 6 4 10 
11-20 2 4 6 
>20 0 7 7 
Total  28 22 50 
 
p=0.001 significant. 
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          ECG evidence*ECHO evidence of PHT: 
ECHO evidence of PHT ECG evidence of PHT 
Present Absent  
Total  
Present   18 5 23 
Absent  4 23 27 
Total  22 28 50 
 
p- Not significant. 
          Pulmonary artery catheterization is the gold standard for measurement 
of pulmonary artery pressure. If we take Doppler echocardiogram 
measurement of pulmonary arterial pressure as the standard procedure, 
sensitivity and specificity of ECG evidence of pulmonary hypertension can 
be measured by Wilson score. 
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          Screening test evaluation: 
Parameters Estimates Lower –upper 95% CI’s
Sensitivity 81.82% (61.48,92.69) Wilson 
score 
Specificity 82.14% (64.41,92.12)  Wilson 
score 
Positive predictive 
value 
78.26% (58.1,90.34)    Wilson 
score 
Negative predictive 
value  
85.19% (67.52,94.08)   Wilson 
score  
Diagnostic accuracy 82% (69.2,90.23)      Wilson 
score 
Likelihood ratio of 
positive test 
4.589 3.022-6.947 
Likelihood ratio of 
negative test 
0.2213 0.1331-0.3681 
Diagnostic odds 20.7 4.844-88.45 
          Electrocardiography has high sensitivity and specificity in the 
detection of pulmonary hypertension. 
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DISCUSSION 
        In our study chronic obstructive airways disease is present almost 
exclusively in males. This is due to increased prevalence of smoking in males. 
According to literatures after standardization for smoking males are at high risk 
than females52 .                                                                                                                             
          Most of the chronic obstructive airways disease patients start smoking at 
an earlier age especially in teen years. Normally lung growth is maximal by the 
late teenage years, and lung function is relatively constant until the late 20s. 
Smoking teenagers do not achieve the peak value of their non smoking 
contemporaries and begin to lose lung function as soon as growth ceases. 
          ECG and ECHO evidence of pulmonary hypertension is more common 
in smokers who smoke more than 20 cigarettes/day than those smoke less or 
those who do not smoke. 
          The role of smoking in the pathogenesis of chronic obstructive airways 
disease received considerable attention in the 1960s. By the late 1970s, it was 
clear that the earliest lesions demonstrable in smokers affected the small 
airways- i.e., small bronchi and bronchioles48, 49.  
           The harmful effects of smoking can be manifested primarily by catarrh 
as well as by limitation of flow. Of these two types, the catarrhal is more 
common; it occurs in about 80% of smokers. Also, the volume of sputum  
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production is not directly related to limitation of airflow50, 51. In some persons, 
the predominant effect of smoking may be hypertrophy of mucous glands and 
hyper secretion; in others, it may damage small airways, destroy alveolar walls, 
and modify elastic recoil of the lungs. 
           In a 40 year follow up of British physicians, the annual mortality per 
100,000 from chronic obstructive airways disease was 10 for those who never 
smoked and 225 for those who smoked more than 25 cigarettes daily; rates 
were intermediate for former smokers and those who smoked fewer than 25 
cigarettes per day57.Many people with a significant number of pack –years still 
have a normal or near normal FEV1 while some people have reduced 
FEV1with relatively modest smoking history. Whether low tar cigarette brands 
produce less severe chronic obstructive airways disease (analogous to 
bronchogenic carcinoma) is unclear. Smokers are not a reliable source of 
information about their own smoke inhalation, and there is no simple means of 
quantifying smoking patterns to determine the connection between patterns of 
smoke inhalation and development of chronic obstructive airways disease. It’s 
not possible to predict which 15% of smokers go on to develop chronic 
obstructive airways disease.          
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           Chronic obstructive airways disease is more common in persons around 
50 years of age. This is attributed to age related decline in FEV1. 
          Chronic obstructive airways disease is more common in manual workers 
of which most of them have been exposed to smoking since teen years. The 
high prevalence of smoking among workers has been a major confounding 
factor. 
          72% of chronic obstructive airways disease patients are from lower socio 
economic status. These may be related to the possible low birth weight (Barker 
hypothesis), childhood malnutrition or damp housing facilities. 
           In our studies16% of   patients have pulseoximetry evidence of 
hypoxemia. According to American Thoracic Society they are candidates for 
long term home oxygen. 
          In our studies 46% of patients has ECG evidence of right ventricular 
strain .34% of persons have ECG evidence of p pulmonale. According to ATS 
they are candidates for long term home Oxygen at a higher saO2 level. 
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          Studies involving ECG evidence of pulmonary hypertension in 
COAD patients  
          According to literatures 58 many patients have ECG changes suggestive 
of RV strain but didn’t manifest RV strain by Echocardiography. 
          Fishman-standard criteria for right ventricular hypertrophy in ECGs were 
absent in 2/3rd of chronic obstructive airways disease patients who had right 
ventricular hypertrophy on post mortem examination59. 
          ECG of prognostic importance in severe chronic obstructive airways 
disease has been outlined by Kok-Jensaw60.In a study of 288 patients survival 
was very poor in individuals with a QRS axis of +90 degrees to +180 degrees 
and amplitude of p wave in lead П of 2mm or more. Only 37% & 47% 
respectively of patients with these changes were alive after 4 years. 
          In V.K.Singh and S.K.Jain study61 of 130 patients of chronic obstructive 
airways disease effect of airflow obstruction on ECG findings such as 
p>2.5mm, QRS axis equal or more than +90 degrees, R wave inV6 less than or 
equal to 5mm, R/S ratio in V5, V6 equal to or less than 1 shows a negative 
correlation with FEV1/FVC ratio. Other features like T wave amplitude, 
negative “p” wave in avL, S wave more than 5mm in depth in V5, V6 and SІ, 
SП, SШ patterns were observed less frequently and correlate weakly with 
severity of disease. 
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          In a study involving 50 plantation workers attending General Hospital, 
Tata Tea Ltd, Munnar, Kerala good correlation between severity of COAD and 
number of abnormal ECG manifestations was present62. 
          In a case control study involving 50 cases& 50 controls age and sex 
matched ECG features of RAD and RV strain, and ECHO features of right 
chambers and pulmonary artery enlargements were compared. According to the 
study sub clinical cor pulmonale and severity of right sided haemodynamic 
disturbances can be measured accurately63. 
          In a study involving 25 COAD patients of R G Kar medical college, 
Calcutta, ECG and ECHO findings were compared. ECG evidence of RVH i.e. 
P pulmonale, right axis deviation, RBBB, clockwise rotation was present in 
50% of patients. ECHO evidence of right ventricular hypertrophy and elevated 
pulmonary artery pressure were found in 85% of cases64.          
          In our study 44% of patients have ECHO evidence of elevated 
pulmonary artery pressure.4 patients had right artrial dilatation.1 patient had 
pericardial effusion. Both right atrial enlargement and pericardial effusion 
show poor prognosis. 
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          Prevention is better than cure. 
          Primordial prevention. 
          COAD is more prevalent in smokers: more in those who smoke more 
than 20 cigarettes/ day: more in those who started smoking in teen years. So 
health education regarding ill effects of smoking should be given to public 
especially school children. 
          Primary prevention. 
           Avoidance of smoking. 
           Wearing protective equipments during working hours in dusty 
occupation. 
           Secondary prevention. 
           Early diagnosis of COAD by clinical methods, chest x-ray and 
pulmonary function test. 
          Tertiary prevention. 
          Treatment of acute exacerbations and early detection of pulmonary 
hypertension by ECG and ECHO. Long term home oxygen is the only proven 
treatment to arrest pulmonary hypertension. Arterial blood gas analysis is very 
useful in the selection of candidates for long term home oxygen therapy. If the 
blood gas analysis facility is not available pulse oximetry can be employed.           
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CONCLUSION 
• In my study Chronic obstructive airways disease is more common in 
males. 
 
• Smoking is the principle cause of Chronic obstructive airways 
disease. 
 
• Severity of Chronic obstructive airways disease is directly 
proportional to intensity of smoking. 
 
• Severity of Chronic obstructive airways disease is associated with 
earlier age of onset of smoking especially in teen ages. 
• Most patients are in low socioeconomic status. 
 
• Electrocardiography has high sensitivity in detecting pulmonary  
hypertension in Chronic obstructive airways diseased  patients as evidenced by 
P pulmonale,right axis deviation,right ventricular hypertrophy .Majority of the 
patients with electrocardiographic evidence of pulmonary hypertension also 
had Echocardiographic evidence of elevated pulmonary artery pressure. So 
both Electrocardiography and Echocardiography are very useful in the 
assessment of severity of chronic obstructive airways disease.  
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 ECG showing P pulmonale, right axis deviation, RVH with strain (R/s > 1 
in V1,r/S <1in V5,V6),QR in avR, QR in V1(right atrial enlargement ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ECG showing P pulmonale, RAD, RVH with strain(R/s> 1 in V1,r/S <1in 
V5,V6), QR in avR. 
 
 
 
 
 
 
 
 
 
 
 
 ECG showing P pulmonale, RAD, QR in avR, R/s >1 in V1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                        
 Echo showing right atrial and right ventricular dilatation in a COAD 
patient.  
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ABBREVIATIONS 
          COAD—Chronic Obstructive Airways Disease 
          COPD – Chronic Obstructive Pulmonary Disease. 
          WHO- World Health Organization.  
          FEV1- Forced Expiratory volume in one second.  
          FVC-Forced Vital Capacity. 
          TNF alpha- Tumor Necrosis Factor alpha. 
          IL-Interleukin. 
          CD-Cluster of Differentiation. 
          ROS-Reactive Oxygen species. 
          Alpha-1 AT--alpha 1 Anti trypsin. 
          RTI-Respiratory Tract Infection. 
          TB-Tuberculosis. 
          GOLD –Global initiative for Obstructive Lung Disease 
          AR –Autosomal Recessive. 
          LHS –Lung Health Study. 
          SI.NO –Serial Number. 
          BA-Bronchial Asthma. 
          H/O-History Of. 
           
           U.K-United kingdom. 
          ICU-Intensive care Unit. 
          FER-Forced Expiratory Ratio. 
          TLCO-carbon monoxide transfer factor. 
          DCO-Diffusing Capacity of Carbon monoxide. 
          KCO-diffusing coefficient. 
          PAP- Pulmonary Artery Pressure. 
          FRC-Functional Residual Capacity. 
          TLC-Total Lung Capacity. 
          RV-Residual Volume. 
          MVV-Maximum Voluntary Ventilation. 
          LTB-Leukotrine B. 
          B.M.R.-Basal Metabolic Rate. 
          B.M.I. - Body Mass Index. 
          PA- Postero Anterior. 
          ATS- American Thoracic Society. 
          ARTP- Association of Respiratory Technicians & Physiologists. 
          BTS- British Thoracic Society. 
 
  
          PHT- Pulmonary hypertension. 
          AFB- Acid Fast Bacilli. 
          PFT- Pulmonary Function Test. 
          NHLBI- National Heart Lung Blood Institute. 
          RA- Right Atria. 
          RV- Right Ventricle. 
          LV- Left Ventricle. 
          PE- Pericardial Effusion. 
          TR- Tricuspid Regurgitation. 
          RBBB- Right Bundle Branch Block. 
          USA- United States of America. 
          ECG- Electrocardiography. 
          ECHO- Echocardiography. 
          BNP— B-type Natriuretic Peptide. 
          RHC- Right Heart Catheterization. 
          CT scan- Computerized Tomographic scan. 
          AMJ- American Medical Journal. 
 
          RAD- Right Axis Deviation. 
          LAD- Left Axis Deviation. 
          P2-Pulmonary component of second heart sound. 
          Ca- Carcinoma. 
          NA- Normal Axis. 
PROFORMA                                                      
          Biodata:      
          Name 
          Age   
          Sex 
          Occupation –factory worker, mine worker  
          Income 
          Residence                                                                                                                   
          Symptoms: 
• Cough with expectoration 
• Dyspnea 
• Chest pain 
• Puffiness of face 
• Swelling of legs 
• Palpitation 
• Syncope 
 
          Past medical history: 
•    Tuberculosis 
•    Systemic hypertension 
    
•    Diabetes Mellitus 
•    Bronchial asthma 
•    Previous hospitalization with similar episode 
 
          Personal history: 
• Smoking –cigarettes –number of packs/day 
         -age at which started smoking 
         - Passive smoking. 
• pan chewing 
• alcohol intake 
• damp housing 
          Family history: 
• Similar episode in the family 
 
          General examination: 
• Mental state 
• Pallor 
• Icterus 
• Cyanosis 
 • polycythemia 
• Pedal edema 
• Jugular venous pulse & pressure –increased or normal- a wave or v   
wave 
• Pursed lip breathing 
• Presence of wasting/Body mass index 
• Blood pressure measurement  
 
          Examination of Respiratory system:    
• Shape of the chest - increased AP diameter 
                                   -  Barrel shaped chest  
                                    -horizontal ribs. 
                                    -splaying of lower costal margin. 
                                    -widened xiphisternal angle. 
•  Paradoxical inward movement of lower ribs  
                during inspiration (HOOVER’S SIGN) 
• movements of chest –chest expansion  
                                       -normal or decreased. 
 
 • Cardiac dullness –normal or decreased. 
• Breath sounds-normal or decreased. 
 
          Cardiovascular system: 
•  Visible pulsation over pulmonary area 
•  Parasternal heave 
• Palpable P2 
• Ejection systolic murmur & Early diastolic murmur over pulmonary 
area 
• Pan systolic murmur over Tricuspid area 
 
          Abdomen: 
• Tender hepatomegaly 
• Ascites 
          Investigations: 
• Hemoglobin  
• X-ray chest PA view  
• Mantoux test 
• Sputum for acid fast bacilli 
 • Pulse oximetry 
• Pulmonary function test –spirometry 
• Electrocardiography 
• Echocardiography 
MASTER CHARTS 
 
PFT SI 
No 
 
Name 
 
Sex Age Smoking Air 
pollution FEV1 FVC FEV1/ FVC 
1 Saleem Male  41 Present Present 1.2  2.1 57  
2 Raji Female 45 Absent Present 1.2 2.1 57  
3 Meyyappan Male 42 Absent Present 1.3 2.1 62 
4 Paulraj Male  53 Present Present 1 2 50 
5 Ezhumalai Male  60 Present Present 1.2 2.1 57 
6 Joseph Male  47 Absent Absent 1.3 2.1 62 
7 Santhosh  Male  41 Absent Present 1,.3 2.1 62 
8 Muniyandi  Male  50 Absent Present 1 1.9 55 
9 Ravi  Male  44 Present Absent 1.2 2.1 55 
10 Ashok  Male  43 Absent Present 1.3 2.1 62 
11 Mustafa Male  48 Present Present 1.3 2.1 62 
12 Jayaram Male  55 Present Present 1.3 2.1 62 
13 Sekar Male  47 Present Present 0.9 1.8 50 
14 Chockalingam Male  60 Present Present 0.9 1.9 47 
15 Vinodh  Male  48 Present Present 1.3 2.1 62 
16 Ibrahim  Male  49 Present Present 1.4 2.1 67 
17 Kanniyappan  Male  55 Absent Present 1.3 2.1 62 
18 Mohammed  Male  60 Present Present 1.2 2.1 55 
19 Govindan  Male  55 Present Present 0.9 1.8 50 
20 Ezhumalai  Male  71 Absent  Absent 1.3 2.1 62 
21 Kannan  Male  48 Absent Present 1.3 2.1 62 
22 Jagadesan  Male  59 Present Present 0.7 1.7 42 
23 Govindasamy  Male  55 Present Present 0.8 1.7 48 
24 Aravind  Male  45 Absent  Present 1.3 2.1 62 
25 Siva lingam  Male  59 present Absent 1.3 2.1 62 
 
 
PFT SI. 
No 
Name Sex Age Smoking Air  
pollution FEV1 FVC FEV1/ 
FVC 
26 Stephen Male 52 Present Present 1.3 2 66 
27 Afzal Male 45 Present Present 1.3 2.1 62 
28 Ramaiah Male 60 Present Present  1.3 2.1 62 
29 Srinivasan Male 51 Absent Absent 1.2 2 60 
30 Palani Male 55 Present Present 0.6 1.2 50 
31 Sankar Male 47 Present Present 1.3 2.1 62 
32 Sivaram Male 43 Absent Present 1.3 2.1 62 
33 Vivek Male 59 Present Present 1.1 2.1 52 
34 Yousuf Male 45 Present Present 1.3 2.1 62 
35 Noorulla Male 64 Absent Present 1 1.8 55 
36 Kalai Male 45 Present Present 1 1.9 55 
37 Sukumar Male 53 Absent Absent 1.3 2.1 62 
38 Velusamy Male 47 Present Present  1.3 2.1 62 
39 Karthikeyan Male 43 Present Present 1.3 2.1 62 
40 Thirupathi Male 50 Present Present 1.3 2.1 57 
41 Thomas Male 50 Present Present 1.3 2.1 62 
42 Murali Male 48 Present Present 1.3 2.1 62 
43 Peermohammed Male 45 Present Present 1.2 2.1 55 
44 Pachaiyappam Male 70 Present Absent 1.3 2.1 62 
45 Ramasamy Male 41 Present Present 1.3 2.1 62 
46 Daniel Male 43 Present Present 1.3 2.1 62 
47 Deepan Male 71 Present Present 1.2 1.9 63 
48 Saravanan Male 35 Present Present 1.3 2.1 62 
49 Paulraj Male 50 Present Present 1.3 2.1 62 
50 Abdul kadhar Male 47 present Absent 1.3 2 65 
 
 
 
ECG ECHO SI. 
No 
Name 
P wave QRS 
axis 
R/S 
in 
V1 
R/S in 
V6 
RBBB ECG 
evidence 
Of PHT 
RA 
dilatation 
TR PE Elevated 
PAP 
1 Saleem 3 RAD <1 >1 present Present Absent Absent Absent Present 
2 Raji 2.5 RAD <1 >1 present Present Absent Absent Absent Present 
3 Meyyappan 2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
4 Paulraj 3 RAD >1 <1 Absent Present Absent Absent Absent Present 
5 Ezhumalai 1.5 RAD >1 <1 Absent Present Absent Absent Absent present 
6 Joseph 1.5 RAD <1 >1 Absent Absent Absent Absent Absent Absent 
7 Santhosh  1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
8 Muniyandi  1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
9 Ravi  3.5 NA <1 >1 Absent Present Absent Absent Absent Present 
10 Ashok  1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
11 Mustafa 1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
12 Jayaram 2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
13 Sekar 3.5 RAD <1 >1 Absent Present Present Present Absent Present 
14 Chockalingam 3 RAD <1 >1 Absent Present Present Present Present Present 
15 Vinodh  2 NA <1 >1 Absent Absent Absent Absent Absent present 
16 Ibrahim  2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
17 Kanniyappan  2.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
18 Mohammed  2.5 NA <1 >1 Present Absent Absent Present Absent Present 
19 Govindan  3.5 NA <1 >1 Absent present Absent Absent Absent Present 
20 Ezhumalai  1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
21 Kannan  2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
22 Jagadesan  3 LAD >1 <1 Absent Present Present Absent Absent Present 
23 Govindasamy  3 RAD <1 >1 Absent Present Present Present Absent Present 
24 Aravind  1.5 NA <1 >1 Absent Absent Absent Present Absent Absent 
25 Siva lingam  3 NA <1 >1 Absent Present Absent Absent Absent Absent 
 
 
                         ECG               ECHO SI. 
No 
Name 
P wave QRS  
axis 
R/S 
in V1 
R/S in 
V6 
RBBB ECG 
evidence of 
PHT 
RA 
dilatation 
TR PE Elevated  
PAP 
26 Stephen 3.5 NA <1 >1 Absent  Present Absent Absent Absent present 
27 Afzal 1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
28 Ramaiah 3 NA <1 >1 Absent Present Absent Absent Absent Absent 
29 Srinivasan 3 NA <1 >1 Absent Present Absent Absent Absent Absent 
30 Palani 2 RAD <1 >1 Present Present Absent Present Absent present 
31 Sankar 1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
32 Sivaram 2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
33 Vivek 3 NA <1 >1 Present Present Absent Absent Absent present 
34 Yousuf 2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
35 Noorulla 3 NA <1 >1 Absent Present Absent Absent Absent Absent 
36 Kalai 2.5 RAD <1 >1 Absent Present Absent Absent Absent present 
37 Sukumar 2.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
38 Velusamy 1.5 NA <1 >1 Absent Absent Absent Absent Absent present 
39 Karthikeyan 1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
40 Thirupathi 2 RAD <1 >1 present Present Absent Absent Absent present 
41 Thomas 3 RAD <1 >1 Absent Present Absent Absent Absent Absent 
42 Murali 2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
43 Peermohammed 1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
44 Pachaiyappam 2 RAD <1 >1 Absent Present Absent Absent Absent Present 
45 Ramasamy 1.5 NA <1 >1 Absent Absent Absent Absent Absent Absent 
46 Daniel 2 NA <1 >1 Absent Absent Absent Absent Absent Absent 
47 Deepan 3 NA >1 <1 Absent Absent Absent Absent Absent Absent 
48 Saravanan 2.5 RAD <1 >1 Absent Present Absent Absent Absent Present 
49 Paulraj 3 NA <1 >1 Absent Present Absent Absent Absent Present 
50 Abdul kadhar 2 NA <1 >1 Absent Absent Absent Absent Absent Present 
 
 
KEY TO MASTER CHART 
 
 
SI. NO- Serial number. 
PFT – Pulmonary Function Test. 
FEV1- Forced Expiratory Volume in one second. (<80% predicted value is taken into account) 
FVC- Forced Vital Capacity. 
FER (Forced Expiratory Ratio)-FEV1/FVC (<70% is taken into account) 
P wave- > 2.5 mm is taken as p pulmonale. 
QRS RAD- QRS Right Axis Deviation.>90° 
QRS LAD- QRS Left Axis Deviation. <-30° 
QRS NA- QRS Normal Axis-(-30°to +90°) 
ECG- Electrocardiography 
RBBB- Right Bundle Branch Block 
ECG evidence of pulmonary hypertension- p pulmonale, RAD, RBBB, R/s in V1 >1, r/S <1 IN 
v6. 
Elevated pulmonary artery pressure (PAP) - mean PAP 20 mm Hg. 
 
 
 
 
